BARRX is a new treatment option for Barrett’s Esophagus, a condition
that can often result from chronic heartburn or Gastroesophageal Reflux
Disease, commonly referred to as GERD. It is performed by St.Vincent
Salem Hospital Gastroenterologist, Jeffrey Morgan, MD in conjunction
with an upper endoscopy and does not require any incisions or surgery.
BARRX can minimize the risk of developing esophageal cancer if suffering
from Barrett’s Esophagus.
Reasons for the Exam
Barrett's esophagus is the
name given to describe abnormal tissue in the esophagus which can occur
as a result of gastro-esophageal reflux (GERD). These abnormal cells can
become cancerous. The procedure of ablating or removing cells can
prevent the tissue from developing into a cancer. The abnormal cells are
destroyed and new healthy cells replace them.
Upper Endoscopy is usually
performed on an outpatient basis. It is performed with the patient lying
on the left side. For the procedure you will swallow a thin, flexible,
lighted tub called an endoscope. The endoscope transmits an image of the
inside of the esophagus. The physician will view the esophagus with the
endoscope and measure the area that requires treatment. The physician
will then insert a BARRX ablation catheter into the esophagus to deliver
energy to only the abnormal tissue.
This procedure can minimize or prevent abnormal cells from developing into a cancerous condition of the esophagus.
BARRX can minimize your risk of
developing esophageal cancer if you suffer from Barrett's Esophagus. It
is extremely important that you continue with your treatment for GERD on
a long term basis as advised by your physician to prevent further
damage to the lining of the esophagus.
TIF was developed to emulate more invasive surgical techniques, but
from within and completely without incisions and visible scars.
The EsophyX TIF device is completely incisionless and is performed
through the mouth, rather than through an abdominal incision. Typically,
the procedure lasts no more than 30-45 minutes and is performed under
general anesthesia. The procedure reconstructs the antireflux barrier
beween the stomach and the esophagus to restore the competency of the
gastroesophageal junction. Most patients can go home the next day and
return to work within a few days.
In clinical studies, 79% of patients undergoing TIF remained off
daily medications such as Nexium and Prilosec and 70% experienced a
total elimination of the heartburn at five years after incisionless
surgery. Patients undergoing the TIF reserve the possibility of future
surgical options and revisions if they have a relapse of symptoms.
For more information visit: www.curebarretts.com